| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5137d258248f7d51a126917b4cd77e97 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12R2001-01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12R1-01 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N1-205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-741
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23C9-1203 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-01 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-741
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 |
| filingDate |
2016-01-08^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b2f12ba9ea305fd8195b6edc433a979
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5b1e1b9b68406a132bc7cd8a0db1f5d |
| publicationDate |
2017-09-13^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20170103920-A |
| titleOfInvention |
Bacteria-containing compositions for the treatment and / or prevention of gastrointestinal tract, metabolic and / or other diseases and methods of use thereof |
| abstract |
The present invention relates to a novel human intestinal isolate capable of converting L-lysine to butyrate and / or fructose-lysine to butyrate. The novel isolate can be used as a probiotic or supplements to promote the production of butitol in the gastrointestinal tract and can prevent and / or treat conditions or diseases that benefit from the production of butyrate. In addition, the isolate can prevent and / or treat a condition or disease mediated by L-lysine or fructose-lysine or advanced glycation end products caused by pathogenic bacterial overgrowth in the gastrointestinal tract . |
| priorityDate |
2015-01-09^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |